New Year, New Approach: Americans Turning to Weight Loss Drugs Before Gym Memberships in 2025 With recent news of pharmaceutical companies working to develop more accessible pill versions of GLP-1 drugs and promises of next-generation medications on the horizon, the landscape of weight loss is und...
Millions of people around the world benefit from weight-loss drugs based on the incretin hormone GLP-1. These drugs also improvekidney function, reduce the risk of fatal cardiac events, and are linked to protection against neurodegeneration. However, many people stop taking the drugs due to commo...
“We already know that GLP-1-based drugs can lead to weight loss. The molecule that we have attached to GLP-1 affects the so-called glutamatergicneurotransmittersystem, and in fact, other studies with human participants suggest that this family of compounds has significant wei...
The rise of GLP-1 weight loss drugs such as Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Mounjaro may be having a slimming effect on grocery sales, Walmart CEO John Furner said on Wednesday (4 October). The retailer, which is the world’s largest company by revenue,...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia, a sweeping new study suggests. ...
“Appetite is central to hunger and weight.” Current GLP-1 RA efficacy data comes from multiple trials. During STEP 1, a long-term evaluation of semaglutide versus placebo for weight loss in non-diabetic patients with overweight or obesity, more than 6 times the number of patients...
To trigger weight loss, tirzepatide mimics two hormones, GLP-1 and GIP, which stimulate the release of insulin in the body. It quells appetite and slows the rate at which food moves through the stomach, helping patients feel full. Novo Nordisk's weight-loss medication, Wegovy, uses semaglut...
GLP-1 agonistBariatric surgeryLifestyle changesWeight lossThe history of multiple weight loss medications has been a concerning paradox based on an increased cardiovascular risk despite significant reductions in adipose tissue and weight. A new class of weight loss medications could change this past ...
To date, there has not been much specific research on weight loss medications for people with HIV, but data are starting to emerge. As reported at the IAS conference, Marisa Brizzi of the University of Cincinnati and colleaguesevaluated the effect of GLP-1 receptor agonists on metabolic outcomes...
The newer, more potent and generally safe agents that work by stimulating receptors to nutrient-stimulated hormones, such as incretins like glucagon-like peptide-1 (GLP-1), seem to drive this interest. When asked, "How much have you heard, if anything, about a new class of drugs being us...